The implications of marijuana reclassification for the US cannabis industry

The Drug Enforcement Administration (DEA) in the US is reportedly working on reclassifying marijuana as a less dangerous drug, moving it from Schedule III to Schedule I. Cannabis company CEOs see this as a positive step towards normalization and federal acknowledgment of the medicinal benefits of cannabis. Reclassification could lead to more research opportunities, financial benefits, and increased industry growth. This move could also help in easing banking restrictions, attracting more investors, and potentially increasing M&A activity. Despite stock market volatility, the industry sees reclassification as a significant step forward.

Read more on finance.yahoo.com